Zimmer Biomet Holdings Inc. expects the hit it will take from the impending medical device excise tax next year will be lower than prior estimates due to the way it now plans to report the expense on its income statement, Chief Financial Officer James Crines told analysts during the firm’s Oct. 25 third-quarter earnings call.
Previously, the orthopedic device maker had estimated the tax, slated to take effect in January 2013, would cost Zimmer about...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?